Houston gala attendees prescribe $1M for groundbreaking stem cell research

breaking boundaries

The event spotlighted the organization’s strides in regenerative medicine, fueling advancements in adult stem cell therapies for conditions often deemed incurable, such as Parkinson’s Disease, multiple sclerosis, and spinal cord injuries. Photo via Si Vo

There’s a new gala in H-town, folks, and it made its grand, sold-out debut thanks to a power couple known for believing that the sky's the limit when it comes to local philanthropy. Chairs Jessica Rossman and Gordon Bethune piloted the inaugural Hope Biosciences Research Foundation (HBRF) fundraiser on October 26 at the Post Oak Hotel in Uptown Houston.

The evening offered patrons a deeper look into the group’s pioneering work, led by co-founders Donna and Daniel Chang. More than 400 supporters — many of whom have witnessed the impact of HBRF’s clinical trials on their health and the lives of loved ones — were enticed to partake in the event by a host committee helmed by Donae, Bella, and Rob Chramosta.

Sherry Diers and David Gonzales, hosts of the foundation’s Hopeful News Network podcast, shared heartfelt stories from their hands-on experiences with HBRF patients. In a touching moment, high school senior Bella Chramosta recounted her own health journey before announcing the inaugural HBRF Luminary Award recipients — Ema Suljkanovic, Rachel Phillips, and Alayna Nunez. The three Kingwood High School students had raised $1,400 for the foundation, and Houston icon Jim “Mattress Mack” McIngvale proudly presented the award.

HBRF offered a Hope-inspired jewelry pull, sponsored by Thomas Markle Jewelers. Each silver necklace entry doubled as a ticket for a chance to win a diamond version of the necklace — 2.27 carats in 18kt white gold, valued at $7,500. The winning ticket, drawn by Sarah and Phillip Markle, brought cheers from those who purchased necklaces throughout the evening. Guests enjoyed a silent auction chaired by Cathy Jackson, featuring everything from health and beauty experiences to travel packages like golfing at St. Andrews and fishing in Cabo.

Gala-goers were treated to a meaningful musical performance by Faith and Jon Hartlage. Upon departure, each guest received a gift from Hope Biosciences, LLC — a tube of Wondercell gel, an anti-aging product made from stem cell byproducts, as a reminder of the foundation’s impact both inside and outside the lab.

Seen on the scene were Ginger and Dick Hite, Maria and Omar Alaoui, Roslyn Bazzelle Mitchell, Cheryl Byington, Gracie and Bob Cavnar, Anna Dean, Karen and Peter Remington, Dr. Romy Dell’Ario, Jan Duncan, Nene Foxhall, Mandy Kao, Stacey Lindseth, Linda McIngvale, Beth Muecke, Patti Murphy, Jennifer Pinkerton, Rachel and Tom Regan, Dallas Rowdan, Ally Shell, Natalie Wall, Christina Zhou, Tama Lundquist and Dr. Peter Farrell, Stephanie and Gary Loveless, Azeemeh Zaheer, Chris Perry, Gregg Harrison, and Dr. Roland Maldonado.

------

This article originally ran on CultureMap.

FibroBiologics will IPO this week. Photo via Getty Images

Houston regenerative medicine company to IPO, move toward more human trials

ready to list

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.”

O’Heeron was first exposed to the possibilities of fibroblasts as a means of regrowing discs in the spine. Since starting the company in 2008 as SpinalCyte, O’Heeron and FibroBiologics have organically written and filed more than 320 patents. Potential treatments go far beyond spinal surgery to include wound care, cancer, and multiple sclerosis.

According to O’Heeron, the goal in going public is to raise capital for human trials.

“We’ve had really fantastic results with animals and now we’re ready for humans,” he explained in September. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

FibroBiologics is growing with impressive speed. O’Heeron told us that he is hiring as quickly as he is able to find qualified scientists with the expertise to do the one-of-a-kind work required. The company opened a new lab last fall at the UH Technology Bridge, Newlin-Linscomb Lab for Cell Therapies. With its new status as a publicly traded company, FibroBiologics is primed to break even more ground.

FibroBiologics is opening a unique new lab at the University of Houston's Technology Bridge. Photo by Natalie Harms/InnovationMap

Houston regenerative medicine company opens new lab at UH

cell therapy innovation

Pete O’Heeron wants you to know that “Bohemian Rhapsody” was originally released as a B-side. What does this nugget about Queen have to do with regenerative medicine? For O’Heeron and his company, FibroBiologics, it means everything.

That’s because most scientists consider stem cells the A-side when it comes to the race to curing disease. But FibroBiologics has set its sights on fibroblasts. The most common cell in the body, fibroblasts are the main cell type in connective tissue.

“Everyone was betting on stem cells, and we started betting on fibroblasts,” says O’Heeron, who started the company in 2008 as SpinalCyte. “I think what we're going to see is that fibroblasts are going to end up winning, there are more robust, more that are lower cost cell, they have higher therapeutic values, higher immune modulation. They're just a better overall cell than the than the stem cells.”

Since a neurosurgeon and a dermatologist first introduced O’Heeron to the idea of using fibroblasts to regrow discs in the spine, the company has expanded its reach to include promising treatments for multiple sclerosis and cancer and in wound care. Imagine a world where doctors lay fibroblasts directly onto surgical incisions after surgery, cutting the time for healing in half.

FibroBiologics has organically written and filed more than 320 patents.

“It's quite a unique situation. I don’t think that in other areas of science that you have such a wide open area to go out and patent. It's just it was a brand new area nobody had been working on,” O’Heeron explains.

And soon, investors will be able to own a stake in the impressive work being forged in Houston. FibroBiologics, previously FibroGenesis, was formed in order to go public in a direct NASDAQ listing. The goal is to access the capital necessary to go to human trials. Earlier this year, the company also launched a crowdfunding campaign.

“We’ve had really fantastic results with animals and now we’re ready for humans,” says O’Heeron. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

With that in mind, the company just signed a deal with University of Houston’s Innovation Center. On Thursday, September 7, FibroBiologics will dedicate the Newlin-Linscomb Lab for Cell Therapies in the UH Technology Bridge. The new lab is named for former player and color commentator for the Houston Rockets, Mike Newlin and his wife, Cindy, as well as Pam and Dan Linscomb, a founding partner of Kuhl-Linscomb, one of the largest wealth management companies in Houston.

Other big local names newly attached to the company are astronaut Kate Rubins and Elizabeth Shpall, the director of the cell therapy laboratory at MD Anderson Cancer Center. Both have joined FibroBiologics as members of its scientific advisory board.

To fill the lab, O’Heeron says that he is adding to his team as quickly as he is able. The barrier is the fact that there are few, if any people in the world with the exact qualifications he’s seeking.

“Anytime you're breaking new scientific ground, you can't really just go out and recruit someone with that background because it really doesn't exist,” he says. But he is willing to teach and challenge scientists who are the right fit, and is hoping to expand the team in the new lab.

But like Queen did in 1975, FibroBiologics is pioneering a category of its own. And that’s something worth betting on.

A Houston research team is studying the effects of regenerative medicine on hearts. Photo via TMC.org

Innovative Houston lab works with 'ghost hearts' to study impact of regenerative medicine

stem cell magic

Ask any high achiever and they’ll tell you — failure is the path to success.

As Camila Hochman-Mendez puts it, “I’m like Thomas Edison, right? I know a thousand ways of how not to create a lightbulb.” But she’s not really talking about electricity. Hochman-Mendez is director of Regenerative Medicine Research and the Biorepository Core at Texas Heart Institute.

Hochman-Mendez follows another pioneering woman in the role, Doris Taylor. The younger scientist took on the prime job when Taylor left in 2020. By then, Hochman-Mendez had been at The Texas Heart Institute for three years, moving from research scientist to assistant director in just four months.

Regenerative Medicine is every bit as exciting as it sounds. At Hochman-Mendez’s lab, her team creates ghost hearts — organs from which all cells are scrubbed, leaving collagen, fibronectin, and laminin in the shape of the formerly beating ticker. The goal is to use the decellularized organs as protein scaffolds that, once injected with stem cells, will once again contract and pump blood.

Hochman-Mendez cautions that we are still years away from that point, but her lab is working hard to get there.

“The ultimate goal is to develop functional hearts that can be used for transplant,” says Hochman-Mendez.

Those hearts would be made from the patient’s own cells, avoiding organ rejection, which the scientist says is essentially trading one disease for another. But she is realistic about that fact that there are many barriers to her success.

“It does come with a lot of technical challenges,” she says.

These challenges include the simple number of cells that billions, and potentially hundreds of billions of cardiomyocytes are needed to recreate a human heart. The necessary protocols, Hochman-Mendez explains, are extremely costly and labor intensive.

It also takes 60 days for the cells to reach a maturity at which they can function. The lab recently received a pair of grants targeted at creating bioreactors that can be reliable for at least those 60 days.

The third major issue facing the Regenerative Medicine lab is contamination.

“It needs to be very sterile,” says Hochman-Mendez. “It needs to be so clean that if you have one tiny bacteria there, you’re screwed.”

Fortunately, the scientist says that her favorite hobby is computer programming. She and a physician colleague have created a robotic arm that can help to prevent the contamination that often stemmed from humans manually injecting stem cells into the decellularized organs.

This not only works towards solving the contamination problem, it also allows the team to more accurately distribute the cells that they add, using an injection map. To that end, she is producing a three-dimensional model of a protein scaffold that will allow her team and other scientists in the field of regenerative medicine to understand how the cells really disperse when they inject them.

When will her lab produce working hearts?

“I try to be very conservative on timing,” she says.

She explains that it will take significant leaps in technology to make a heart mature to the level at which it’s usable for an adult body in 60 days.

“That’s magic and I don’t believe in magic,” she says, but adds that she hopes to have a prototype ready to be tested in five years.

Hochman-Mendez does this all with a small team of nine researchers, most of whom happen to be female.

“The best candidates are the ones that I select," she says. "The majority are females. I think it’s a mix of trying to be very unbiased, but I usually don’t even look at the name before looking at the CV to preselect the people that I interview.”

And together, Hochman-Mendez are making medical history, one success-spawning failure at a time.

Camila Hochman-Mendez is director of Regenerative Medicine Research and the Biorepository Core at Texas Heart Institute. Photo via texasheart.org

The new biotech accelerator has already worked with two companies, which have relocated their operations to Houston. Getty Images

Houston millionaire starts biotech accelerator for companies focusing on regenerative medicine

Stem cell-erator

A new Houston-based startup accelerator is planning to advance companies focusing on regenerative medicine and stem cell treatment.

Houston Healthspan Innovation Group was created by founder and CEO Ed Bosarge, a local entrepreneur who's made millions of developing health care and finance technology.

"From day one, Houston Healthspan will play a significant role in shaping Houston's vibrant life sciences scene with its seasoned leadership and state-of-the-art facilities," Bosarge says in a news release. "Houston Healthspan may be a tipping point for the region's life sciences community."

The program will provide its participating startups and joint venture partners with expertise and resources in biology, clinical disease, therapeutic delivery systems, finance, and marketing, per the release.

The accelerator will be housed out of the Houston Healthspan Bio Labs —10,000 square feet of lab space just south of the Texas Medical Center. The labs will provide the scientists and researchers with cutting-edge technologies, large cleanrooms, and cGMP cell culture workstations will be used for cell manufacturing, bioprocessing, and therapeutic protocol development. The lab can even handle small-scale biologics manufacturing.

"Gaining access to lab space is a significant hurdle many start-up life sciences companies must overcome," says Dr. Steven Greco, chief science officer at Houston Healthspan. "Our Bio Labs address this need and offer a compelling and ideal setting for start-ups and joint-venture partners to conduct pre-clinical studies and obtain valuable research services."

Houston Healthspan has already started working with two regenerative medicine companies that have both relocated their operations to Houston. Rejenevie Therapeutics™, which moved from New Jersey, develops therapies for immune system restoration as well as age-related illnesses. Formerly based in Hawaii, Tissue Genesis created the Icellator X®, a technology that focuses on stem cell isolation.

"With two collaborator companies like Rejenevie and Tissue Genesis working out of our Houston Healthspan Bio Labs, we can offer significant resources and expertise for start-up and joint-venture partners to thrive and succeed," says Eric Schaeffer, chief strategy officer, in the release.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 fast-growing Houston tech companies secure spots on Deloitte list

big wins

Deloitte’s annual North America Technology Fast 500 list includes four Houston companies this year — all boasting of significant growth.

For Houston, Direct Digital Holdings, Inc. took the highest-ranking spot at No. 101 (up from 108 previous year) with 1,184 percent growth. NatGas Hub LLC (No. 286, 407 percent growth), Liongard (No. 437, 246 percent growth), and Stratus Medical LLC (No. 483, 212 percent growth) also made the list, which is an annual ranking of the fastest-growing North American companies in technology, energy tech sectors, telecommunications, life sciences, media, and fintech.

"Houston continues to demonstrate its prowess in fostering growth and technological advancement and I’m incredibly proud to see some of our local companies making significant strides and earning their well-deserved spots on the 2024 Deloitte Technology Fast 500 list,” Houston managing partner at Deloitte Melinda Yee says in a news release.

Award winners were selected based on fiscal year revenue growth from 2019 to 2022.

The companies achieved revenue growth ranging from 201 percent to 153,625 percent over the three-year time frame with an average growth rate of 1,981 percent and a median growth rate of 460 percent, according to a news release. Texas accounts for 6 percent of the winning companies with 73 percent of the companies from Texas are in the software sector.

“These companies exemplify the entrepreneurial spirit and innovative mindset that define Houston's dynamic business ecosystem,” Yee adds.

In 2023, the Houston representation looked similar. Direct Digital Holdings again topped the Houston rankings at No. 108, with Liongard, NatGasHub.com, and P97 Networks also showing substantial growth. As a state, Texas had 30 companies that made the list of the 541 ranked. In 2022, just one Houston company was recognized, as at No. 372 Onit reported revenue increase of 369 percent.

Biopharmaceutical company TG Therapeutics, Inc. was the No.1 spot in 2024 with a growth rate of 153,625 percent from 2020 to 2023. See the full list here.

Play it back: How this Houston innovator is championing women in health tech

HOUSTON INNOVATORS PODCAST EPISODE 264

With her long-standing career in health care, Ayse McCracken knows women are integral in leading health care. That's why she started Ignite Healthcare Network — to help find, support, and champion female health tech founders.

Originally founded in 2017 as a pitch competition, Ignite has evolved to become an active and integral program for female health tech entrepreneurs. Last month, the organization hosted its annual Fire Pitch Competition, and six finalists walked away with awards. At the event, the founders pitched their health tech solutions across lung health, renal therapy, breastfeeding tech, and more.

Last year, McCracken joined the Houston Innovators Podcast to share her story of starting Ignite and how its evolved since, accelerating around 100 female founders and advancing life-saving health care technology.

"Success to me isn't just getting people an early stage investment," she says on the show. "Success to me is getting companies that actually commercialize, get their products in the market, and that they are actually making an impact on health wellbeing, patients, and so forth."

"Having an impact in the health care industry and finding solutions is important to me," McCracken adds. "The second aspect of that is there are so many women in health care, and yet you don't see them in leadership roles."

Houston urban agricultural nonprofit gears up for opening of new farm in Second Ward

GROWING FOR GOOD

Small Places, a Houston-based urban agricultural nonprofit, is looking forward to putting down roots beyond the fresh vegetables they grow in the East End.

After securing a 40-year land agreement with Harris County, the organization, which provides produce to families facing food insecurity in the Second Ward, is expecting to open their new farm in February 2025. Small Places’ founders hope the 1.5 acres of land named Finca Tres Robles, located at 5715 Canal Street, will be the beginning of Houston’s urban farming movement.

Founded in 2014 by brothers Daniel, Mark, and Thomas Garcia-Prats, Small Places was born out of the latter brother’s desire to work on an organic farm in his hometown of Houston. After farming in Maine, Iowa, and Nicaragua, Thomas had hoped to manage an urban farm but was unable to find a place. He then roped his brothers, who had no agricultural background at the time, into creating one.

“I joke that my journey in agriculture started the day we started out there. We didn’t grow up gardening or farming or anything of the sort,” says Daniel, Small Places’ director of operations. “It was a big learning curve, but how we approached it to our benefit was through our diverse set of backgrounds.”

Small Places began their need-based produce distribution programs through a partnership with nearby pre-school, Ninfa Lorenzo Early Childhood Center, providing food insecure families with fresh produce and later cooking lessons in 2017. When COVID-19 hit Houston in 2020, Daniel says Small Places pivoted towards becoming a redistribution center for their farming contacts who needed to offload produce as restaurants shut down, selling their crops through the organization. Their neighborhood produce program was then born, providing free boxes of produce to nearly 200 families in the East End at the pandemic’s peak.

“We found ourselves in the middle of two communities who were in need, one being people in our community who were losing jobs and were in need of food as well as our farming connections who were losing restaurant accounts,” Daniel explains.

Small Places grows a variety of vegetables at their East End based farm, selling them at a weekly farm stand. (Photo courtesy Small Places)

Small Places currently assists 65 families living predominantly within two miles of their original location and they recently restarted their programming with Ninfa Lorenzo Early Childhood Center, and accepts Supplemental Nutrition Assistance Program benefits (SNAP) at their farm stand. Daniel says once Finca Tres Robles opens, Small Places plans to bring back cooking classes and educational seminars on healthy eating for which his brother Mark, a former teacher, created the original curriculum. The farm will also have a grocery store stocked with Finca Tres Robles' produce and eventually food staples from local vendors.

“Being social and preparing a meal can be fun, interesting, and delicious. Being able to pull all of that into a program was really important for us,” Daniel explains.

Farming successfully in the middle of Houston for their subsidized programs and produce market requires Small Places’ team to be strategic in their operations. Using his background in engineering and manufacturing, Daniel says they’ve closely monitored trends in which crops perform the best in Houston’s varied, humid climate over the past decade.

They also follow Thomas’s philosophy of allowing nature to work for them, planting crops at times when specific pests are minimal or integrating natural predators into their environment. And lots of composting. Daniel says they accept compostable materials from community members, before burying the raw organic matter in the earth in between their plant beds, allowing it to mature, then later using it to nourish their crops. Daniel says he and his co-founders hope to see more community-focused, sustainable operations like theirs spring up across Houston.

“Small Places is about hopefully more than one farm and really trying to turn urban agriculture and a farm like ours from a novel thing into something that’s just a part of communities and the fabric of Houston for generations to come,” Daniel says.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME